Abstract
Transplantation across the ABO barrier is sometimes done in cases of emergency, such as acute liver failure, but is also carried out in elective cases, e.g. kidneys from living donors. Reducing the recipient anti-A/B antibody titres is often necessary in ABO-incompatible kidney transplantation. This is usually done by the use of techniques such as plasmapheresis and protein A- or sepharose-linked anti-human Ig immunoadsorption. A new ABO immunosorbent with synthetic A- or B-trisaccharide carbohydrate epitopes linked to a sepharose matrix has been tested. Columns made of this material have been tested in vitro with plasma from A- and B-individuals, assessed for antibody reduction capacity, flow characteristics, biocompatibility, and unspecific protein adsorption. The columns have a high capacity for ABO antibody removal, reducing titres by three to seven steps in one passage. We noted a high biocompatibility, with no unspecific protein adsorption, no activation of coagulation factors, and a low activation of complement, no immune complex formation and no cytotoxicity towards cultured mammalian L929 cells.
Similar content being viewed by others
References
Berkman EM, Caplan S, Kim CS. ABO-incompatible bone marrow transplantation: preparation by plasma exchange and in vivo antibody adsorption. Transfusion 1978; 18:504.
Osterwalder B, Gratwohl A, Nissen C, Speck B. Immunoadsorption for removal of anti-A and anti-B blood group antibodies in ABO-incompatible bone marrow transplantation. Blut 1986; 53:379.
Alexandre GPJ, de Bruyere M, Latinne D, et al. ABO-incompatible related and unrelated living donor renal allografts. Transplant Proc 1986; 18:452.
Rydberg L. ABO-incompatible solid organ transplantation. Transfus Med 2001; 11:325.
Wu A, Bühler LH, Cooper DKC. ABO-incompatible organ and bone marrow transplantation: current status. Transpl Int 2003; 16:201.
Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65:224.
Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. In vitro and in vivo removal of anti-A erythrocytic antibody by adsorption to a synthetic immunoadsorbent. Transfusion 1981; 21:335.
Agishi T, Takahashi K, Ota K, Yagisawa T. Comparative evaluation of immunoadsorption and double filtration plasmapheresis for removal of anti-A and anti-B antibody in ABO-incompatible kidney transplantation. Transplant Proc 1992; 24:557.
Gjörstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfus Sci 1990; 11:281.
Leventhal JR, John R, Fryer JP, et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation 1995; 59:294.
Tarkowski A, Czerkinsky C, Nilsson LÅ. Simultaneous induction of rheumatoid factor and antigen-specific antibody-secreting cells during secondary immune response in man. Clin Exp Immunol 1985; 61:379.
Bengtsson A, Svalander C, Mölne J, Rydberg L, Breimer ME. Extracorporeal (“ex vivo”) connection of pig kidneys to humans. III Studies of plasma complement activation and complement deposition in the kidney tissue. Xenotransplantation 1998; 5:176.
Rydberg L, Björck S, Hallberg E, et al. Extracorporeal (“ex vivo”) connection of pig kidneys to humans II. The anti-pig antibody response. Xenotransplantation 1996; 3:340.
Holgersson J, Breimer ME, Samuelsson BE. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. Acta Pathol Microbiol Immunol Scand Suppl 1992; 27:18.
Takahashi K. ABO-incompatible kidney transplantation. Elsevier Science, Amsterdam, the Netherlands, 2001.
Rieben R, Korchagina EY, von Allmen E, et al. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunosorbents. Transplantation 1995; 60:425.
Rydberg L, Breimer ME, Holgersson J, et al. Characterization of the anti-A antibody response following an ABO (A2 to O) kidney transplantation. Residual anti-A type 1 chain specific antibody activity after adsorption with A1 erythrocytes and Synsorb-A. Mol Immunol 1992; 29:547.
Dodd BE, Lincoln PJ, Boorman KE. The cross-reacting antibodies of group O sera. Immunological studies and possible explanation of the observed facts. Immunology 1967; 12:39.
Contreras M, Armitage SE, Hewitt PE. Response to immunisation with A and B human glycoproteins for the procurement of blood grouping reagents. Vox Sang 1984; 47:224.
Hed J, Johansson M, Lindroth M. Complement activation according to the alternate pathway by glass and plastic surfaces and its role in neutrophil adhesion. Immunol Lett 1984; 8:295.
Hyllner M, Arnestad JP, Bengtsson JP, Rydberg L, Bengtsson A. Complement activation during storage of whole blood, red cells, plasma and buffy coat. Transfusion 1997; 37:264.
Åvall A, Hyllner M, Bengtsson JP, Carlsson L, Bengtsson A. Greater increase in cytokine concentration after salvage with filtered whole blood than with washed red blood cells, but no difference in post-operative hemoglobin recovery. Transfusion 1999; 39:271.
Nelson PW, Helling TS, Shield CF, Beck M, Bryan CF. Current experience with renal transplantation across the ABO barrier. Am J Surg 1992; 164:541.
Acknowledgements
This study was supported by grants from the Swedish Medical Research Council (grant 11621) and the EU Shared Cost Biotechnology Programme. Lola Svensson and Lisbeth Selvén are acknowledged for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rydberg, L., Bengtsson, A., Samuelsson, O. et al. In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transpl Int 17, 666–672 (2005). https://doi.org/10.1007/s00147-004-0775-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00147-004-0775-7